AbbVie Shares Drop 6% Amid Concerns About Humira (NYSE:ABBV) Sales Slump by Technical Terrence Team 04/26/2024 0 vzfotos AbbVie Stock (New York Stock Exchange: ABBV) fell 6% in afternoon trading Friday in the wake of the drugmaker's ...
Survey Reveals GLP-1 Users More Likely to Undergo Cosmetic Procedures (NYSE:ABBV) by Technical Terrence Team 03/17/2024 0 Svitlana Hulkó Users of GLP-1 drugs such as Ozempic, Wegovy and Zepbound are more likely to undergo cosmetic procedures, which ...
Next big wave of patent cliffs ahead; biopharmaceutical M&A expected to increase (NYSE:ABBV) by Technical Terrence Team 02/19/2023 0 Olivier LeMoal With a significant number of blockbuster drugs at risk of losing market exclusivity in the next five years, ...
AbbVie’s global bestseller Humira will face imitations this week (NYSE:ABBV) by Technical Terrence Team 01/29/2023 0 vzphotos After generating $208 billion in sales over two decades, AbbVie's (New York Stock Exchange: ABBV) the monopoly on its ...
The Last Worker Review: Unconvincing Dismantling of Capitalist Megastructures Lacks Conviction | Games 04/06/2023
Crypto is bound to be hard to regulate, but at least the Treasury wants to try | John Naughton 02/25/2023